Literature DB >> 11710822

Failure-specific prognostic factors after continuous hyperfractionated accelerated radiotherapy (CHART) or conventional radiotherapy in locally advanced non-small-cell lung cancer: a competing risks analysis.

O U Ataman1, S M Bentzen, M I Saunders, S Dische.   

Abstract

The aim of this study was to identify possible failure-specific prognostic factors in non-small-cell lung cancer. Clinical outcome was analysed in 549 patients participating in the randomized controlled trial of CHART vs conventional radiotherapy. Local failure and distant failure with or without concurrent local relapse were subjected to a competing risk analysis using an accelerated failure-time model with a log-logistic hazard function. Randomization to CHART (2 P = 0.005), increasing age (2 P = 0.036) and female sex (2 P = 0.09) was all associated with a prolonged interval to failure. Advanced clinical stage was associated with a decreased interval to failure (2 P = 0.004) and a significantly increased risk (2 P = 0.009) of failing in distant rather than in local position. From this model, prognostic indices for local and distant failure were estimated for each individual patient. Competing risk analysis allows identification of patients with different failure patterns, and may provide a means of stratifying patients for intensified local or systemic therapy. Copyright 2001 Cancer Research Campaign http://www.bjcancer.com.

Entities:  

Mesh:

Year:  2001        PMID: 11710822      PMCID: PMC2375163          DOI: 10.1054/bjoc.2001.2049

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  16 in total

1.  Direct estimation of latent time for radiation injury in late-responding normal tissues: gut, lung, and spinal cord.

Authors:  S M Bentzen; H D Thames; E L Travis; K K Ang; E Van der Schueren; L Dewit; D O Dixon
Journal:  Int J Radiat Biol       Date:  1989-01       Impact factor: 2.694

2.  Regression and recursive partition strategies in the analysis of medical survival data.

Authors:  A Ciampi; J F Lawless; S M McKinney; K Singhal
Journal:  J Clin Epidemiol       Date:  1988       Impact factor: 6.437

3.  A method of analysis taking into account competing events: application to the study of digestive complications following irradiation for cervical cancer.

Authors:  A Kramar; M H Pejovic; D Chassagne
Journal:  Stat Med       Date:  1987 Oct-Nov       Impact factor: 2.373

4.  A randomised phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable non-small cell lung cancer: final report of an Australian multi-centre trial.

Authors:  D Ball; J Bishop; J Smith; P O'Brien; S Davis; G Ryan; I Olver; G Toner; Q Walker; D Joseph
Journal:  Radiother Oncol       Date:  1999-08       Impact factor: 6.280

Review 5.  Novel approaches to locally advanced unresectable non-small cell lung cancer.

Authors:  C W Stevens; J S Lee; J Cox; R Komaki
Journal:  Radiother Oncol       Date:  2000-04       Impact factor: 6.280

6.  Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): identification of five groups with different survival.

Authors:  M Werner-Wasik; C Scott; J D Cox; W T Sause; R W Byhardt; S Asbell; A Russell; R Komaki; J S Lee
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-12-01       Impact factor: 7.038

7.  Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience.

Authors:  K S Albain; J J Crowley; M LeBlanc; R B Livingston
Journal:  J Clin Oncol       Date:  1991-09       Impact factor: 44.544

8.  Prognostic factors in osteosarcomas. A regression analysis.

Authors:  S M Bentzen; H S Poulsen; S Kaae; O M Jensen; H Johansen; H T Mouridsen; S Daugaard; C Arnoldi
Journal:  Cancer       Date:  1988-07-01       Impact factor: 6.860

9.  Competing events determining relapse-free survival in limited small-cell lung carcinoma. The French Cancer Centers' Lung Group.

Authors:  R Arriagada; A Kramar; T Le Chevalier; H De Cremoux
Journal:  J Clin Oncol       Date:  1992-03       Impact factor: 44.544

10.  Induction chemotherapy followed by concurrent standard radiotherapy and daily low-dose cisplatin in locally advanced non-small-cell lung cancer.

Authors:  A Ardizzoni; F Grossi; T Scolaro; S Giudici; F Foppiano; L Boni; L Tixi; M Cosso; C Mereu; G B Ratto; V Vitale; R Rosso
Journal:  Br J Cancer       Date:  1999-09       Impact factor: 7.640

View more
  1 in total

1.  Association between polymorphisms of epidermal growth factor 61 and susceptibility of lung cancer: A meta-analysis.

Authors:  Quan Chen; Yiming Zheng; Bingbing Wu; Xia Chen; Pengfei Ge; Pengcheng Wang
Journal:  Medicine (Baltimore)       Date:  2020-04       Impact factor: 1.817

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.